1.Kessler, RC, Chiu, WT, Demler, O, Merikangas, KR, Walters, EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:617–627.
2.Kessler, RC, Berglund, P, Delmer, O, Jin, R, Merikangas, KR, Walters, EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:590–592.
3.Murray, CJ, Lopez, AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet. 1997;349:1436–1442.
4.Zheng, D, Macera, CA, Croft, JB, Giles, WH, Davis, D, Scott, WK. Major depression and allcause mortality among white adults in the United States. Ann Epidemiol. 1997;7:213–218.
5.Cuijpers, P, Smit, F. Excess mortality in depression: a meta-analysis of community studies. J Affect Disord. 2002;72:227–236.
6.Rivelli, S, Jiang, W. Depression and ischemic heart disease: what have we learned from clinical trials? Curr Opin Cardiol. 2007;22:286–291.
7.Taylor, MJ, Freemantle, N, Geddess, JR, Bhagwagar, Z. Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. Arch Gen Psychiatry. 2006;63:1217–1223.
8.Irwin, MR, Miller, AH. Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav Immun. 2007;21:374–383.
9.Dantzer, R, O'Connor, JC, Freund, GG, Johnson, RW, Kelley, KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9:45–46.
10.Raison, CL, Capuron, L, Miller, AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27:24–31.
11.Penninx, BW, Kritchevsky, SB, Yaffe, K, et, al. Inflammatory markers and depressed mood in older persons: results from the Health, Aging and Body Composition Study. Biol Psychiatry. 2003;54:566–572.
12.Bremmer, MA, Beekman, AT, Deeg, DJ, et, al. Inflammatory markers in late-life depression: results from a population-based study. J Affect Disord. 2008;106:249–255.
13.Zorrilla, EP, Luborsky, L, McKay, JR, et al.The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun. 2001;15:199–226.
14.Tuglu, C, Kara, SH, Caliyurt, O, Vardar, E, Abay, E. Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology (Berl). 2003;170:429–433.
15.Myint, AM, Leonard, BE, Steinbusch, HW, Kim, YK. Th1, Th2, and Th3 cytokine alterations in major depression. J Affect Disord. 2005;88:167–173.
16.Leonard, BE. The immune system, depression and the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry. 2001;25:767–780.
17.Kenis, G, Maes, M. Effects of antidepressants on the production of cytokines. Int J Neuropsychopharmacol. 2002;5:401–412.
18.Hestad, KA, Tønseth, S, Støen, CD, Ueland, T, Aukrust, P. Raised plasma levels of tumor necrosis factor alpha in patients with depression: normalization during electroconvulsive therapy. J Ect. 2003;19:183–188.
19.Eller, T, Vasar, V, Shlik, J, Maron, E. Pro-inflammatory cytokines and treatment response to escitaloprsam in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2008,15;32:445–450.
20.van den Biggelaar, AH, Gussekloo, J, de Craen, AJ. Inflammation and interleukin-1 signaling network contribute to depressive symptoms but not cognitive decline in old age. Exp Gerontol. 2007;42:693–701.
21.Campbell, SJ, Deacon, RM, Jiang, Y, Ferrari, C, Pitossi, FJ, Anthony, DC. Overexpression of IL-1 beta by adenoviral-mediated gene transfer in the rat brain causes a pro-longed hepatic chemokine response, axonal injury and the suppression of spontaneous behaviour. Neurobiol Dis. 2007;27:151–63.
22.Reyes, TM, Coe, CL. Interleukin-1 beta differentially affects interleukin-6 and soluble interleukin-6 receptor in the blood and central nervous system of the monkey. J Neuroimmunol. 1996;66:135–141.
23.Levine, J, Barak, Y, Chengappa, KN, Rapoport, A, Rebey, M, Barak, V. Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology. 1999;40:71–76.
24.Foster, SL, Hargreaves, DC, Medzhitov, R. Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature. 2007;447:972–978.
25.Asnis, GM, De La Garza, R 2nd. Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches. J Clin Gastroenterol. 2006;40:322–335.
26.Taylor, JL, Grossberg, SE. The effects of interferon-alpha on the production and action of other cytokines. Semin Oncol. 1998;25:23–29.
27.Juengling, FD, Ebert, D, Gut, O. Prefrontal cortical hypometabolism during low-dose interferon alpha treatment. Psychopharmacology (Berl). 2000;152:383–389.
28.Tanaka, H, Maeshima, S, Shigekawa, Y, et, al. Neuropsychological impairment and decreased regional cerebral blood flow by interferon treatment in patients with chronic hepatitis: a preliminary study. Clin Exp Med. 2006;6:124–128.
29.Michie, HR, Manogue, KR, Spriggs, DR, et, al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl Med. 1988;318:1481–1486.
30.Suffredini, AF, Hochstein, HD, McMahon, FG. Dose-related inflammatory effects of intravenous endotoxin in humans: evaluation of a new clinical lot of Escherichia coli 0:113 endotoxin. J Infect Dis. 1999;179:1278–1282.
31.Reichenberg, A, Yirmiya, R, Schuld, A, et, al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry. 2001;58:445–452.
32.Wright, CE, Strike, PC, Brydon, L, Steptoe, A. Acute inflammation and negative mood: mediation by cytokine activation. Brain Behav Immun. 2005;19:345–350.
33.Müller, N, Schwarz, MJ, Dehning, S, et, al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry. 2006;11:680–684.
34.Tyring, S, Gottlieb, A, Papp, K, et, al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet. 2006;367:29–35.
35.Simen, BB, Duman, CH, Simen, AA, Duman, RS. TNF alpha signaling in depression and anxiety: behavioral consequences of individual receptor targeting. Biol Psychiatry. 2006;59:775–785.
36.Benton, T, Staab, J, Evans, DL. Medical co-morbidity in depressive disorders. Ann Clin Psychiatry. 2007;19:289–303.
37.Elenkov, IJ. Neurohormonal-cytokine interactions: implications for inflammation, common human diseases and well-being. Neurochem Int. 2008;52:40–51.
38.Huffman, JC, Smith, FA, Quinn, DK, Fricchione, GL. Post-Ml psychiatric syndromes: six unanswered questions. Harv Rev Psychiatry. 2006;14:305–318.
39.Constant, A, Castera, L, Dantzer, R, et al.Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. J Clin Psychiatry. 2005;66:1050–1057.
40.Bower, JE. Cancer-related fatigue: links with inflammation in cancer patients and survivors. Brain Behav Immun. 2007;21:863–871.
41.Stewart, JC, Janicki, DL, Muldoon, MF, Sutton-Tyrrell, K, Kamarck, TW. Negative emotions and 3-year progression of subclinical atherosclerosis. Arch Gen Psychiatry. 2007;64:225–233.
42.Papakostas, GI, Nutt, DJ, Hallett, LA, Tucker, VL, Krishen, A, Fava, M. Resolution of sleepiness and fatigue in major depressive disorder: a comparison of bupropion and the selective serotonin reuptake inhibitors. Biol Psychiatry. 2006;60:1350–1355.
43.Capuron, L, Pagnoni, G, Demetrashvili, MF, et al.Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy. Neuropsychopharmacology. 2007;32:2384–2392.
44.Neumeister, A. Tryptophan depletion, serotonin, and depression: where do we stand? Psychopharmacol Bull. 2003;37:99–115.
45.Müller, N, Schwarz, MJ. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry. 2007;12:988–1000.
46.Capuron, L, Neurauter, G, Musselman, DL, et al.Interferon-alpha-induced changes in tryptophan metabolism. Relationship to depression and paroxetine treatment. Biol Psychiatry. 2003;54:906–914.
47.Pittenger, C, Sanacora, G, Krystal, JH. The NMDA receptor as a therapeutic target in major depressive disorder. CNS Neurol Disord Drug Targets. 2007;6:101–115.
48.Palucha, A, Pilc, A. Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs. Pharmacol Ther. 2007;115:116–147.
49.Sanacora, G, Gueorguieva, R, Epperson, CN, et al.Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry. 2004;61:705–713.
50.Bhagwagar, Z, Wylezinska, M, Jezzard, P, et al.Reduction in occipital cortex gamma-aminobutyric acid concentrations in medication-free recovered unipolar depressed and bipolar subjects. Biol Psychiatry. 2007;61:806–812.
51.Berman, RM, Cappiello, A, Anand, A, et al.Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351–354.
52.Zarate, CA Jr, Singh, JB, Carlson, PJ, et al.A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63:856–864.
53.Zarate, CA Jr, Payne, JL, Quiroz, J, et al.An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry. 2004;161:171–174.
54.Sanacora, G, Kendell, SF, Levin, Y, et al.Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry. 2007;61:822–825.
55.Saito, K, Crowley, JS, Markey, SP, Heyes, MP. A mechanism for increased quinolinic acid formation following acute systemic immune stimulation. J Biol Chem. 1993;268:15496–15503.
56.Myint, AM, Kim, YK, Verkerk, R, Scharpé, S, Steinbusch, H, Leonard, B. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affect Disord. 2007;98:143–151.
57.Fedele, E, Foster, AC. An evaluation of the role of extracellular amino acids in the delayed neurodegeneration induced by quinolinic acid in the rat striatum. Neuroscience. 1993;52:911–917.
58.Pocock, JM, Kettenmann, H. Neurotransmitter receptors on microglia. Trends Neurosci. 2007;30:527–535.
59.Shibakawa, YS, Sasaki, Y, Goshima, Y, et al.Effects of ketamine and propofol on inflammatory responses of primary glial cell cultures stimulated with lipopolysaccharide. Br J Anaesth. 2005;95:803–810.
60.Rosi, S, Vazdarjanova, A, Ramirez-Amaya, V, Worley, PF, Barnes, CA, Wenk, GL. Memantine protects against LPS-induced neuroinflammation, restores behaviorally-induced gene expression and spatial learning in the rat. Neuroscience. 2006;142:1303–1315.
61.Danbolt, NC. Glutamate uptake. Prog Neurobiol. 2001;65:1–105.
62.Bergles, DE, Jahr, CE. Glial contribution to glutamate uptake at Schaffer collateral-commissural synapses in the hippocampus. J Neurosci. 1998;18:7709–7716.
63.Rothstein, JD, Dykes-Hoberg, M, Pardo, CA, et al.Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron. 1996;16:675–686.
64.Tanaka, K, Watase, K, Manabe, T, et al.Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science. 1997;276:1699–1702.
65.Vercellino, M, Merola, A, Piacentino, C, et al.Altered glutamate reuptake in relapsing-remitting and secondary progressive multiple sclerosis cortex: correlation with microglia infiltration, demyelination, and neuronal and synaptic damage. J Neuropathol Exp Neurol. 2007;66:732–739.
66.McEwen, BS. Glucocorticoids, depression, and mood disorders: structural remodeling in the brain. Metabolism. 2005;54(5 suppl 1):20–23.
67.Duman, RS, Monteggia, LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 2006;59:1116–1127.
68.Fuchs, E, Czéh, B, Kole, MH, Michaelis, T, Lucassen, PJ. Alterations of neuroplasticity in depression: the hippocampus and beyond. Eur Neuropsychopharmacol. 2004;14(suppl 5):S481–S490.
69.Block, ML, Zecca, L, Hong, JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci. 2007;8:57–69.
70.Li, L, Lu, J, Tay, SS, Moochhala, SM, He, BP. The function of microglia, either neuroprotection or neurotoxicity, is determined by the equilibrium among factors released from activated microglia in vitro. Brain Res. 2007;1159:8–17.
71.Hanisch, UK, Kettenmann, H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci. 2007;10:1387–1394.
72.Pinteaux, E, Rothwell, NJ, Boutin, H. Neuroprotective actions of endogenous interleukin-1 receptor antagonist (IL-1ra) are mediated by glia. Glia. 2006;53:551–556.
73.Hutchinson, PJ, O'Connell, MT, Rothwell, NJ, et al.Inflammation in human brain injury: intracerebral concentrations of IL-1alpha, IL-1 beta, and their endogenous inhibitor IL-1 ra. J Neurotrauma. 2007;24:1545–1557.
74.Qin, L, Wu, X, Block, ML, et al.Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia. 2007;55:453–462.
75.Maeda, J, Higuchi, M, Inaji, M, et al.Phase-dependent roles of reactive microglia and astrocytes in nervous system injury as delineated by imaging of peripheral benzodiazepine receptor. Brain Res. 2007;1157:100–111.
76.Mastronardi, C, Whelan, F, Yildiz, OA, et al, Caspase 1 deficiency reduces inflammation-induced brain transcription. Proc Natl Acad Sci USA. 2007;104:7205–7210.
77.Tikka, TM, Koistinaho, JE. Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia. J Immunol. 2001;166:7527–7533.
78.Ishikawa, J, Ishikawa, A, Nakamura, S. Interferon-alpha reduces the density of monoaminergic axons in the rat brain. Neuroreport. 2007;18:137–140.
79.Hashioka, S, Klegeris, A, Monji, A, et al.Antidepressants inhibit interferon-gamma-induced microglial production of IL-6 and nitric oxide. Exp Neurol. 2007;206:33–42.
80.Hannestad, J, Levanti, MB, Vega, JA. Distribution of neurotrophin receptors in human palatine tonsils: an immunohistochemical study. J Neuroimmunol. 1995;58:131–137.
81.García-Suáez, O, Hannestad, J, Esteban, I, Sainz, R, Naves, FJ, Vega, JA. Expression of the TrkB neurotrophin receptor by thymic macrophages. Immunology. 1998;94:235–241.
82.Asami, T, Ito, T, Fukumitsu, H, Nomoto, H, Furukawa, Y, Furukawa, S. Autocrine activation of cultured macrophages by brain-derived neurotrophic factor. Biochem Biophys Res Commun. 2006;344:941–947.
83.Martinowich, K, Manji, H, Lu, B. New insights into BDNF function in depression and anxiety. Nat Neurosci. 2007;10:1089–1093.
84.Rajkowska, G, Miguel-Hidalgo, JJ. Gliogenesis and glial pathology in depression. CNS Neurol Disord Drug Targets. 2007;6:219–233.
85.Nägler, K, Mauch, DH, Pfrieger, FW. Glia-derived signals induce synapse formation in neurones of the rat central nervous system. J Physiol. 2001;533(pt 3):665–679.
86.Ullian, EM, Sapperstein, SK, Christopherson, KS, Barres, BA. Control of synapse number by glia. Science. 2001;291:657–661.
87.Kim, JP, Choi, DW. Quinolinate neurotoxicity in cortical cell culture. Neuroscience. 1987;23:423–432.
88.Myint, AM, Kim, YK. Cytokine-serotonin interaction through IDO: a neurodegeneration hypothesis of depression. Med Hypotheses. 2003;61:519–525.
89.Tapia, R. Release and uptake of glutamate as related to excitotoxicity. Rev Bras Biol. 1996;56(suppl 1,pt 1):165–174.
90.Lobsiger, CS, Cleveland, DW. Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease. Nat Neurosci. 2007;10:1355–1360.
91.Frizzo, ME, Dall'Onder, LP, Dalcin, KB, Souza, DO. Riluzole enhances glutamate uptake in rat astrocyte cultures. Cell Mol Neurobiol. 2004;24:123–128.
92.Fatemi, SH, Laurence, JA, Araghi-Niknam, M, et al.Glial fibrillary acidic protein is reduced in cerebellum of subjects with major depression, but not schizophrenia. Schizophr Res. 2004;69:317–323.
93.Si, X, Miguel-Hidalgo, JJ, O'Dwyer, G, Stockmeier, CA, Rajkowska, G. Age-dependent reductions in the level of glial fibrillary acidic protein in the prefrontal cortex in major depression. Neuropsychopharmacology. 2004;29:2088–2096.
94.Haddy, N, Sass, C, Maumus, S, et al.Biological variations, genetic polymorphisms and familial resemblance of TNF-alpha and IL-6 concentrations: STANISLAS cohort. Eur J Hum Genet. 2005;13:109–117.
95.de Kloet, ER, Joëls, M, Holsboer, F. Stress and the brain: from adaptation to disease. Nat Rev Neurosci. 2005;6:463–475.